$ファイザー(PFE.US)$$ノボ・ノルディスク(NVO.US)$$アクサム セラピューティクス(AXSM.US)$$マクロジェニックス(MGNX.US)$ 1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly. 2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
SlowndEasyTradesSalmon Klein:
Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon KleinSlowndEasyTrades:
I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
SlowndEasyTradesSalmon Klein:
Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway
10baggerbamm :
no matter what time frame of a chart you pull up daily weekly monthly yearly it's a complete disaster. 10 years of wealth destroyed since covid.
1.$Annovis Bio Inc(ANVS.US)$ • Ph 3 data (also Ph 2/3 in AD). • Buntanetap for Parkinson’s Disease. • Exp Jan '24 but delayed (est this qtr). 2.$アクサム セラピューティクス(AXSM.US)$ • Ph 3 data (SYMPHONY). • AXS-12 for Narcolepsy. • AXS-12 has Orphan Drug Designation. 3.$G1セラピューティクス(GTHX.US)$ • Ph 3 Overall Survival (OS) data. • Trilaciclib (combo) for breast cancer (mTNBC). • DMC recommended continuation earlier in Feb. 4.$クリネティック ファーマシューティカルズ(CRNX.US)$ • Ph 3 data (PATHFND...
The strong revenue growth mirrors the robust share price gain. Top performers like Axsome Therapeutics can continue winning for decades. This seems like a good opportunity, despite the already positive sentiment.
Despite being loss-making, Axsome Therapeutics' strong cash position and revenue increase provide a positive outlook. It's projected to improve its free cash flow with further revenue growth.
Axsome Therapeutics' 66% projected growth rate may be overly optimistic. A slower growth rate might push the break-even point further, and the high debt level of 63% of its equity amplifies the investment risk in the unprofitable company.
Pre-Market Stock Movers Gapping up $Sagimet Biosciences(SGMT.US)$ (Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.) $イーライ リリィ(LLY.US)$ (The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...
15
1
2
報告
MonkeyGee :
Don't let the premarket trick you. wait for the open to trade. many times the algo uses the premarket to set the tone for the opening because the trades are lighter during premarket which allows them to have easier control over the price. Let's see where PLTR goes this week!
Salmon Klein : are you in $マクロジェニックス (MGNX.US)$ ? tell me when good to jump in
MangoXXXX Salmon Klein: Now
SlowndEasyTrades Salmon Klein: Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon Klein SlowndEasyTrades: I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
SlowndEasyTrades Salmon Klein: Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway